Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

What’s New in Treatment: IgA Vasculitis & IgA Nephropathy

  |  

Samantha C. Shapiro, MD, is the executive editor of Harrison’s Principles of Internal Medicine. As a clinician educator, she practices telerheumatology and writes for both medical and lay audiences.

References

  1. Thalen M, Gisslander K, Segelmark M, et al. Epidemiology and clinical characteristics of biopsy-confirmed adult-onset IgA vasculitis in southern Sweden. RMD Open. 2024;10(1):e003822.
  2. Neumann T. Update on immunoglobulin A vasculitis. Z Rheumatol. 2022;81(4):305–312.
  3. Audemard-Verger A, Pillebout E, Amoura Z, et al. Gastrointestinal involvement in adult IgA vasculitis (Henoch-Schönlein purpura): Updated picture from a French multicentre and retrospective series of 260 cases. Rheumatology (United Kingdom). 2020;59(10):3050–3057.
  4. Pillebout E, Alberti C, Guillevin L, et al. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int. 2010;78(5):495–502.
  5. Hernández-Rodríguez J, Carbonell C, Mirón-Canelo JA, et al. Rituximab treatment for IgA vasculitis: A systematic review. Autoimmun Rev. 2020;19(4):102490.
  6. Wheeler DC, Toto RD, Stefánsson B V., et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215–224.
  7. Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2):391–402.
  8. Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. The Lancet. 2023 Sep 9;402(10405):859–870.
  9. Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024 Jan 4;390(1):20–31.
  10. Lafayette R, Maes B, Lin C, et al. #3848 origin trial: 24-wk primary analysis of a randomized, double-blind, placebo-controlled ph2B study of atacicept in patients with IgAN. Nephrol Dial Transplant. 2023 Jun;38(suppl 1).
  11. Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023 Dec 2;402(10417):2077–2090.

Related Articles
    ilusmedical / shutterstock.com

    The State of Clinical Research in Vasculitis: 2021

    It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

    Tips for Diagnosing, Treating Seldom Seen Forms of Vasculitis

    WASHINGTON, D.C.—The vast majority of the attention given to vasculitis at the ACR/ARHP Annual Meeting, year after year, focuses on ANCA-associated vasculitis and large-vessel vasculitis, said Philip Seo, MD, MHS, director of the Johns Hopkins Vasculitis Center and moderator of the 2016 ACR Review Course titled, Neglected Vasculitis. That leaves out a lot. “These are…